Mechanisms of GZ17-6.02 resistance
Sign Up to like & getrecommendations! Published in 2022 at "Anti-Cancer Drugs"
DOI: 10.1097/cad.0000000000001203
Abstract: Objectives The drug GZ17-6.02 is undergoing phase I in solid tumor patients (NCT03775525). The present studies initially determined the impact of prolonged exposure of colorectal tumors to GZ17-6.02, and to determine whether GZ17-6.02 enhanced the… read more here.
Keywords: gz17; tumor cells; efficacy; hdac inhibitors ... See more keywords
GZ17-6.02 Inhibits the Growth of EGFRvIII+ Glioblastoma
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms23084174
Abstract: Epidermal Growth Factor Receptor (EGFR) is amplified in over 50% of glioblastomas and promotes tumor formation and progression. However, attempts to treat glioblastoma with EGFR tyrosine kinase inhibitors have been unsuccessful thus far. The current… read more here.
Keywords: growth; gz17; inhibits growth; gz17 inhibits ... See more keywords